Grandaxin

Grandaxin is a prescription medication that contains the benzodiazepine‑derived anxiolytic Tofisopam. It is supplied in oral dosage form, with strength and specific formulation varying by market, and is authorized for use within the European Union. Tofisopam acts on the GABA‑A receptor to reduce anxiety without producing marked sedation, distinguishing it from many traditional benzodiazepines. It is classified under ATC code N05BA09 and is prescribed for short‑term management of anxiety symptoms.

Grandaxin (tofisopam) is indicated for the treatment of anxiety‑related conditions in adult patients.

- Management of generalized anxiety disorder (GAD) where persistent worry interferes with daily functioning - Treatment of situational or stress‑related anxiety, such as performance anxiety or travel‑induced nervousness - Use as an adjunct for patients who experience excessive sedation with conventional benzodiazepines, offering anxiolysis with reduced drowsiness - Short‑term relief of acute anxiety episodes, for example during panic attacks or heightened stress periods - Consideration in specialist‑guided off‑label protocols for certain sleep‑related anxiety disturbances

The safety profile of Grandaxin reflects its pharmacologic activity on the central nervous system; side effects are reported as either common and generally mild or, less frequently, serious. While most patients experience only mild symptoms, clinicians monitor for less common but potentially serious reactions.

Common: - Mild drowsiness or fatigue - Light‑headedness or dizziness - Nausea or mild gastrointestinal upset

Serious: - Allergic reactions such as rash, swelling, or difficulty breathing - Mood alterations including depression or emergence of suicidal thoughts - Severe skin reactions (e.g., Stevens‑Johnson syndrome) or significant muscle weakness

When prescribing Grandaxin, healthcare professionals should evaluate individual risk factors and follow precautionary measures to ensure safe use.

- Assess liver and kidney function before initiating therapy, as impairment may affect drug clearance - Use the lowest effective dose for the shortest duration needed to control anxiety - Avoid use in patients with a history of substance misuse or dependence on sedative‑hypnotics - Monitor for signs of depression, suicidal ideation, or behavioral changes during treatment - Caution in elderly patients due to increased sensitivity to central nervous system effects - Discuss potential risks with pregnant or breastfeeding women, as safety data are limited

Grandaxin may interact with other medicines that influence the central nervous system or hepatic metabolism; reviewing a patient’s medication list is essential.

Avoid: - Concomitant use with other benzodiazepines or potent sedatives (e.g., barbiturates, opioids) due to additive CNS depression - Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or certain macrolide antibiotics, which can increase tofisopam plasma levels - Monoamine oxidase inhibitors (MAOIs) or other anxiolytics that may potentiate serotonergic effects

Use with caution: - Alcohol consumption, which can enhance drowsiness and impair coordination - Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), requiring monitoring for mood changes - Anticonvulsants that are metabolized by the same hepatic pathways, such as carbamazepine, may alter drug concentrations